Adult vaccination current recommendations and future prospects

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 1, 2015, Pages 150-155

  Swanson, Kena A ^a   Schmitt, H Josef ^b   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a Vaccine Research East and Early Development   (United States)

^b PFIZER INC   (United States)

Author keywords

Clostridium difficile; Infectious disease; Pneumococcal disease; Staphylococcus aureus; Vaccine

Indexed keywords

BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A VACCINE; CLOSTRIDIUM DIFFICILE TOXIN B VACCINE; CLOSTRIDIUM DIFFICILE VACCINE; CLUMPING FACTOR A VACCINE; DIPHTHERIA TOXOID CRM197; INFLUENZA VACCINE; MANGANESE; NEUTRALIZING ANTIBODY; PNEUMOCOCCUS VACCINE; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ADULT DISEASE; ADULT IMMUNIZATION; AGE DISTRIBUTION; AGING; ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COST CONTROL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG USE; GERIATRIC CARE; GERIATRIC PATIENT; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH IMPACT ASSESSMENT; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; LIFE EXTENSION; MORTALITY; OPSONIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; POSTHERPETIC NEURALGIA; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS INFECTION; TREND STUDY; VACCINE PRODUCTION; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; PROCEDURES; SECONDARY IMMUNIZATION; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES;

EID: 84922599905     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.35858     Document Type: Article

References (66)

1. Whitney CG, Zhou F, Singleton J, Schuchat A; Centers for Disease Control and Prevention (CDC). Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR Morb Mortal Wkly Rep 2014; 63:352-5; PMID:24759657
2. The 2009 Ageing Report: economic and budgetary projections for the EU-27 Member States (2008-2060). Luxembourg: Joint Report prepared by the European Commission (DG ECFIN) and the Economic Policy Committee (AWG). 2009
3. Bureau UC. Population by Age and Sex for the United States: 1900 to 2000. PartA. Census 2000 Special Reports, Series CENSR-4: US Administration on Aging, 2002
4. US Census Bureau PD. Projections of the Population by Age and Sex for the United States: 2010 to 2050. US Census Bureau, Population Division, 2008.
5. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31:501-8; PMID:22327872; http://dx.doi. org/10.1097/INF.0b013e31824de9f6
6. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013; 31:6232-8; PMID:24176490; http://dx.doi.org/10.1016/j. vaccine.2013.10.032
7. Kyaw MH, Rose CE Jr., Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192:377-86; PMID:15995950; http://dx.doi.org/10.1086/431521
8. van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65:17-24; PMID:22394683; http://dx.doi.org/10.1016/j. jinf.2012.02.017
9. Bridges CB, Coyne-Beasley T; Advisory Committee on Immunization Practices (ACIP); ACIP Adult Immunization Work Group; Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:110-2; PMID:24500291
10. Maltezou HC, Wicker S, Borg M, Heininger U, Puro V, Theodoridou M, Poland GA. Vaccination policies for health-care workers in acute healthcare facilities in Europe. Vaccine 2011; 29:9557-62; PMID:21964058; http://dx.doi.org/10.1016/j. vaccine.2011.09.076
11. Esposito S, Montinaro V, Bosis S, Tagliabue C, Baggi E, Principi N. Recommendations for the use of influenza vaccine in pediatrics. Hum Vaccin Immunother 2012; 8:102-6; PMID:22252005; http://dx.doi. org/10.4161/hv.8.1.17957
12. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58; PMID:19124790; http://dx.doi.org/10.1503/ cmaj.080734
13. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422; PMID:23440780
14. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19:353-63; PMID:15180106; http:// dx.doi.org/10.1023/B:EJEP.0000024701.94769.98
15. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802-8; PMID:23000122; http://dx.doi.org/10.1016/j.vaccine.2012.09.019
16. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11; PMID:10902624; http://dx.doi.org/10.1016/S0140-6736(00)02377-1
17. Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408-16; PMID:22457293; http://dx.doi.org/10.1093/ infdis/jis212
18. Törling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22:96-103; PMID:14604576; http://dx.doi. org/10.1016/S0264-410X(03)00521-8
19. consortium S. Vaccination of adults in Europe. 2013
20. Paradiso PR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis 2012; 55:259-64; PMID:22495545; http://dx.doi.org/10.1093/ cid/cis359
21. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193:1487-94; PMID:16652275; http://dx.doi. org/10.1086/503805
22. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al.; Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51; PMID:16249418; http:// dx.doi.org/10.1001/jama.294.16.2043
23. M. Bonten MB. S. Huijts, C. Webber, S. Gault, W. Gruber, D. Grobbee. Community Acquired Pneumonia Immunisation Trial in Adults (CAPITA). ISPPD. Hyperabad, India, 2014.
24. Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, Purdy J, Paradiso P, File TM Jr. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis 2013; 208:1813-20; PMID:24092845; http://dx.doi.org/10.1093/infdis/ jit506
25. L.; Whitney C.G.; Moore M.R.; Jain S.; Edwards K.M.; Self W.H. Gcgwrgwdzybrfscmaeqch. Distribution Of Pneumococcal Serotypes Detected Through Urine Analysis Among Us Adults Hospitalized With Pneumonia After Introduction Of Pcv13. 2014
26. Wegner C, Hübner NO, Gleich S, Thalmaier U, Krüger CM, Kramer A. One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010. [8:Doc12]. GMS Hyg Infect Control 2013; 8:Doc12; PMID:23967398
27. Klein EY, Laxminarayan R. The potential impact of age and season on methicillin-resistant Staphylococcus aureus prevalence. Future Microbiol 2013; 8:809-12; PMID:23841624; http://dx.doi. org/10.2217/fmb.13.65
28. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012; 30:4307-9; PMID:22682287; http://dx.doi.org/10.1016/j. vaccine.2012.01.056
29. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects". Vaccine 2013; 31:2723-30; PMID:23624095; http://dx.doi.org/10.1016/j. vaccine.2013.04.002
30. Donald RG, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology 2013; 159:1254-66; PMID:23629868; http://dx.doi.org/10.1099/mic.0.066712-0
31. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32; PMID:9709046; http:// dx.doi.org/10.1056/NEJM199808203390806
32. Klein E, Smith DL, Laxminarayan R. Communityassociated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg Infect Dis 2009; 15:1925-30; PMID:19961671; http://dx.doi.org/10.3201/eid1512.081341
33. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillinresistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007; 13:1840-6; PMID:18258033; http://dx.doi.org/10.3201/ eid1312.070629
34. Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE. Committee SL-T-C. Clostridium difficile in long-term-care facilities for the elderly. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America 2002; 23:696-703; http://dx.doi. org/10.1086/501997
35. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-36; PMID:19528959; http://dx.doi.org/10.1038/ nrmicro2164
36. Seekatz AM, Young VB. Clostridium difficile and the microbiota. J Clin Invest 2014; 1-8; PMID:25036699
37. Gould IM. Costs of hospital-acquired methicillinresistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents 2006; 28:379-84; PMID:17045462; http://dx.doi.org/10.1016/j. ijantimicag.2006.09.001
38. Dubberke E. Clostridium difficile infection: the scope of the problem. J Hosp Med 2012; 7(Suppl 3):S1-4; PMID:22407993; http://dx.doi.org/10.1002/ jhm.1916
39. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-74; PMID:15756888; http://dx.doi.org/10.1086/502522
40. Cheng AG, DeDent AC, Schneewind O, Missiakas D. A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol 2011; 19:225-32; PMID:21353779; http://dx.doi.org/10.1016/j. tim.2011.01.007
41. Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, Jansen KU. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother 2012; 8:1585-94; PMID:22922765; http://dx.doi.org/10.4161/ hv.21872
42. Broughan J, Anderson R, Anderson AS. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Expert Rev Vaccines 2011; 10:695-708; PMID:21604989; http://dx.doi. org/10.1586/erv.11.54
43. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013; 309:1368-78; PMID:23549582; http://dx.doi. org/10.1001/jama.2013.3010
44. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6; PMID:11844850; http://dx.doi.org/10.1056/NEJMoa011297
45. Brady RA, O'May GA, Leid JG, Prior ML, Costerton JW, Shirtliff ME. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun 2011; 79:1797-803; PMID:21220484; http://dx.doi.org/10.1128/ IAI.00451-10
46. Lattar SM, Noto Llana M, Denoël P, Germain S, Buzzola FR, Lee JC, Sordelli DO. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun 2014; 82:83-91; PMID:24126523; http://dx.doi.org/10.1128/ IAI.01050-13
47. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 2006; 103:16942-7; PMID:17075065; http://dx.doi.org/10.1073/ pnas.0606863103
48. Nanra JS, Buitrago SM, Crawford S, Ng J, Fink PS, Hawkins J, Scully IL, McNeil LK, Aste-Amézaga JM, Cooper D, et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother 2013; 9:480-7; PMID:23249887; http://dx.doi. org/10.4161/hv.23223
49. Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol 2012; 19:1641-50; PMID:22896688; http://dx.doi.org/10.1128/CVI.00354-12
50. Handke LD, Rogers KL, Olson ME, Somerville GA, Jerrells TJ, Rupp ME, Dunman PM, Fey PD. Staphylococcus epidermidis saeR is an effector of anaerobic growth and a mediator of acute inflammation. Infect Immun 2008; 76:141-52; PMID:17954724; http://dx.doi.org/10.1128/ IAI.00556-07
51. Mishra RP, Mariotti P, Fiaschi L, Nosari S, Maccari S, Liberatori S, Fontana MR, Pezzicoli A, De Falco MG, Falugi F, et al. Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. J Infect Dis 2012; 206:1041-9; PMID:22829645; http://dx.doi.org/10.1093/infdis/jis463
52. Korea CG, Balsamo G, Pezzicoli A, Merakou C, Tavarini S, Bagnoli F, Serruto D, Unnikrishnan M. The staphylococcal Esx proteins modulate apoptosis and release of intracellular Staphylococcus aureus during infection in epithelial cells. Infect Immun 2014; PMID:25047846; http://dx.doi.org/10.1128/ IAI.01576-14
53. Becherelli M, Prachi P, Viciani E, Biagini M, Fiaschi L, Chiarot E, Nosari S, Brettoni C, Marchi S, Biancucci M, et al. Protective activity of the CnaBE3 domain conserved among Staphylococcus aureus Sdr proteins. PLoS One 2013; 8:e74718; PMID:24069334; http://dx.doi.org/10.1371/journal. pone.0074718
54. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467:711-3; PMID:20844489; http://dx.doi. org/10.1038/nature09397
55. Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother 2014; 10:1-12; PMID:24832715; http://dx.doi. org/10.4161/hv.28428
56. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W Jr., Nichols R, Edelman R, Bridwell M, Monath TP. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001; 69:988-95; PMID:11159994; http://dx.doi.org/10.1128/ IAI.69.2.988-995.2001
57. Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012; 30:2245-9; PMID:22306375; http://dx.doi. org/10.1016/j.vaccine.2012.01.065
58. Valneva. An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84, NCT01296386. ClinicalTrialsgov, 2014
59. Pfizer. Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years, NCT01706367. ClinicalTrialsgov, 2014
60. Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009; 58:446-58; PMID:19446340; http://dx.doi. org/10.1016/j.jinf.2009.04.001
61. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59(RR-8):1-62; PMID:20689501
62. Williams WW, Lu PJ, O'Halloran A, Bridges CB, Pilishvili T, Hales CM, Markowitz LE; Centers for Disease Control and Prevention (CDC). Noninfluenza vaccination coverage among adults - United States, 2012. MMWR Morb Mortal Wkly Rep 2014; 63:95-102; PMID:24500288
63. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; http://dx.doi. org/10.1056/NEJMoa051016
64. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al.; Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320-8; PMID:22828595; http://dx.doi.org/10.1093/cid/ cis638
65. Kanitz EE, Wu LA, Giambi C, Strikas RA, Levy-Bruhl D, Stefanoff P, Mereckiene J, Appelgren E, D'Ancona F; VENICE (Vaccine European New Integrated Collaboration Effort) National Gatekeepers, Contact Points. Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage. Vaccine 2012; 30:5222-8; PMID:22721901; http://dx.doi.org/10.1016/j. vaccine.2012.06.012
66. Boutriau D. Evaluation of an investigational 4-componant Staphylococcus aureus vaccine with or without AS03B adjuvant in healthy adults: results from a phase 1 trial. International Symposium on Staphylococci and Staphylococcal Infections, Chicago, USA August 26-29 1014